Baxter International Inc BAX

Morningstar Rating
$23.64 −0.36 (1.50%)
View Full Chart

Company Report

Baxter Turnaround Efforts Continue Under New Management Team

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, including inflation and weak medical utilization trends just after making the large Hillrom acquisition. However, elevated medical utilization, supply chain pressures easing, and new contracts with group purchasing organizations coming online since then, Baxter's profits should be in turnaround mode.

Price vs Fair Value

BAX is trading at a d.C premium.
Price
$24.00
Fair Value
!&%
Uncertainty
LOCK|L>&
1-Star Price
fg
5-Star Price
pTs
Economic Moat
LOCK|^<xc
Capital Allocation
LOCK|RSn

Bulls Say, Bears Say

Bulls

In the long run, Baxter should continue to grow at a decent clip, primarily around evolutionary innovation in all of the major business lines and moderate pricing or mix improvements.

Bears

Although Baxter's products are essential for medical care and patient health, GPO contract negotiations can limit pricing power and flexibility.

News

Articles & Videos

Trading Information

Previous Close Price
$24.00
Day Range
$23.48–24.04
52-Week Range
$15.73–30.00
Bid/Ask
$23.50 / $23.89
Shares Outstanding
517.00M
Market Cap
$12.22B
Volume/Avg
7M / 7M

Key Statistics

Price/Earnings (Normalized)
11.76
Price/Sales
1.08
Dividend Yield (Trailing)
0.17%
Dividend Yield (Forward)
0.17%
Dividend Payment Schedule
Jan, Apr, Jul, Oct
Total Yield
0.17%

Company Profile

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Value
Total Number of Employees
37,500

Competitors

Valuation

Metric
BAX
BDX
SYK
Price/Earnings (Normalized)
11.7613.7719.74
Price/Book Value
2.002.004.40
Price/Sales
1.082.534.12
Price/Cash Flow
11.1713.5118.85
Price/Earnings
BAX
BDX
SYK

Financial Strength

Metric
BAX
BDX
SYK
Quick Ratio
1.120.361.08
Current Ratio
1.950.942.16
Interest Coverage
−0.813.53—
Quick Ratio
BAX
BDX
SYK

Profitability

Metric
BAX
BDX
SYK
Return on Assets (Normalized)
4.99%4.97%11.44%
Return on Equity (Normalized)
15.42%10.63%23.97%
Return on Invested Capital (Normalized)
7.44%7.26%14.10%
Return on Assets
BAX
BDX
SYK

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
LOCK|D@>dn<fLOCK|m$$144B
Becton Dickinson & Co
BDX
LOCK|q>LOCK|yPfg$49B
ResMed Inc
RMD
LOCK|TXZB&>F!LOCK|W>zw$32B
Alcon Inc
ALC
LOCK|@jnDX@LOCK|QQr<>$31B
Medline Inc Ordinary Shares - Class A
MDLN
LOCK|W>P&j$$LOCK|vjd<<$30B
West Pharmaceutical Services Inc
WST
LOCK|$NQc?k?LOCK|h&y$26B
Solventum Corp
SOLV
LOCK|G^#l>?LOCK|!B$15B
Repligen Corp
RGEN
LOCK|!??B@PlLOCK|N<!>x$11B
The Cooper Companies Inc
COO
LOCK|mR<%T?DLOCK|mXNm$11B

Sponsor Center